As KRAS-mutant NSCLC tumors are extremely heterogenous, largely due to the diversity of their genetic alterations [9], comparing KRAS-mutant phenotypes using patient samples or NSCLC cell lines is challenging. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.